News Stories

JACKSONVILLE, Fla. and ORANGEBURG, N.Y., March 02, 2021 -- The National Lipid Association (NLA), the preeminent global authority on lipid disorders, and Paradigm Medical Communications, LLC (Paradigm), a multiple award-winning medical education company, are proud to announce their collaborative partnership to design and implement How Low Do You Go? Novel Strategies to Address LDL-C Limbo, an 18-month blended learning, certified continuing education curriculum for clinicians, comprising live and online activities, to launch in May 2021.

Be sure to make plans to join us in June (VIRTUALLY) and September (IN-PERSON) for our premier educational events in 2021:

Summer of Lipids: A Virtual Education Experience with the NLA · June 4-6, 2021

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.